Eupraxia Pharmaceuticals【EPRX】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

4.65

買値

4.65

売値

4.69

出来高

7,700

4.65 日の範囲 4.74

3.07 52 週間の範囲 7.64

時価総額

126.861M

前日終値

4.66

始値

4.74

時刻

100

4.65

最終取引時間

01:09:44

財務取引量

VWAP

平均取引量 (3 か月)

32,126

発行済株式数

27,282,000

配当利回り

PER

-4.50

1 株当たり利益 (EPS)

-1.03

歳入

純利益

-28.22M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.eupraxiapharma.com

本社

Victoria, British Columbia, Can

設立

Eupraxia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the トロント証券取引所 with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was $4.66. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of $ 3.07 to $ 7.64.

Eupraxia Pharmaceuticals currently has 27,282,000 shares in issue. The market capitalisation of Eupraxia Pharmaceuticals is $127.13 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.50.

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, Nov. 12, 2024 One...

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024 VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million PR Newswire VICTORIA, BC, Oct. 31, 2024 VICTORIA, BC, Oct. 31, 2024 /PRNewswire/...

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 PR Newswire VICTORIA, BC, Oct. 28, 2024 VICTORIA, BC, Oct. 28, 2024 /PRNewswire/...

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis PR Newswire VICTORIA, BC, Oct. 15, 2024 Publication...

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 PR Newswire VICTORIA, BC, Oct. 10, 2024 VICTORIA, BC, Oct. 10, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Eupraxia Pharmaceuticals Strengthens Senior Management Team PR Newswire VICTORIA, BC, Oct. 2, 2024 VICTORIA, BC, Oct. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.33	-6.6265060241	4.98	4.98	4.41	13283	4.70334859	CS
4	0	0	4.65	5.45	3.89	32178	4.56748931	CS
12	1.24	36.3636363636	3.41	5.45	3.07	32126	4.08172993	CS
26	0.91	24.3315508021	3.74	5.45	3.07	23236	3.90441002	CS
52	-0.95	-16.9642857143	5.6	7.64	3.07	33095	4.3391422	CS
156	2.73	142.1875	1.92	9.1	0.8	27662	4.25300364	CS
260	-3.1	-40	7.75	9.1	0.8	25253	4.23464231	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
LEVLion Electric Company	$ 0.48 (18.52%)	4.09M
DIAMStar Diamond Corporation	$ 0.035 (16.67%)	20.32k
AVLAvalon Advanced Materials Inc	$ 0.04 (14.29%)	20.86k
ORVOrvana Minerals Corp	$ 0.275 (12.24%)	82.71k
MUXMcEwen Mining Inc	$ 12.91 (10.15%)	43.05k
SCYScandium International Mining Corp	$ 0.015 (-25.00%)	92k
AMCArizona Metals Corp	$ 1.69 (-13.78%)	1.4M
GMTNGold Mountain Mining Corp	$ 0.035 (-12.50%)	9.78k
BKIBlack Iron Inc	$ 0.085 (-10.53%)	214.4k
BUBurcon NutraScience Corporation	$ 0.09 (-10.00%)	205.18k
LEVLion Electric Company	$ 0.48 (18.52%)	4.09M
BNSBank of Nova Scotia	$ 77.18 (-3.27%)	3.77M
BTEBaytex Energy Corp	$ 3.99 (0.50%)	2.39M
BITFBitfarms Ltd	$ 2.79 (-2.79%)	2.13M
LUCLucara Diamond Corp	$ 0.53 (0.00%)	1.99M